Summary
- Profile Type
- Business Offer
- POD Reference
- BOPL20250417011
- Term of Validity
- 16 June 2025 - 16 June 2026
- Company's Country
- Poland
- Type of partnership
- Supplier agreement
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Polish biotechnological company is specialised in a production of hyaluronic acid-based products and offers a wide range of supplements, medicinal products, medical devices and care solutions on the state-of-the-art level. The company is looking for foreign partners from the veterinary sector in order to expand their presence on the local and global markets.
- Full Description
-
The Polish biotechnological company, present in nearly 60 countries, specialises in hyaluronic acid-based products tailored to the needs of both patients and medical professionals, as well as to veterinary sector. It operates in five key sectors: orthopaedic, spine care, dental surgery, aesthetic medicine, and pharmaceuticals. Each of these areas reflects their commitment to providing effective, targeted healthcare solutions.
Their portfolio includes supplements, medicinal products, medical devices, and care solutions – all developed based on advanced scientific research:
Medicinal Products and Supplements
• hyaluronic acid for intra-articular injections for the treatment of joint diseases, available in three variants depending on the animal’s size.
• a veterinary medicinal product containing hyaluronic acid for intravenous or subcutaneous injection. Supports joint mobility, reduces lameness, swelling, and pain.
Dietary Supplements
• supports cartilage regeneration and joint function, available as syrup or tablets, contains glucosamine, chondroitin, MSM, and hyaluronic acid.
• a liver support formulation with plant extracts rich in antioxidants, vitamins, and minerals. Promotes cell regeneration and detoxification.
• a blend of probiotics, prebiotics, and vitamins supporting gut flora, absorption, and peristalsis.
• contains CBD-rich hemp oil, vitamins A and D, and omega acids from salmon oil. Offers calming and anti-inflammatory effects and supports neurological therapy (e.g., epilepsy).
• helps maintain acid-base balance, reduces phosphate levels, and protects kidney function.
• supports oncological therapy in animals. Olive leaf and ginseng extracts boost immunity, inhibit tumor growth, and induce apoptosis.
Care Products
• wound care solution with polyhexanide and chitosan. Accelerates healing and protects against infection.
• for eye and skin care. Stabilises the tear film, creates a protective barrier, reduces inflammation, and supports regeneration.
Medical Devices
• an advanced PRP (Platelet-Rich Plasma) separation device for animal blood. Achieves a 7.8-fold platelet concentration, ideal for treating tendinopathies and degenerative joint diseases.
• an innovative bone substitute based on hydroxyapatite and tricalcium phosphate. Available in blocks, wedges, granules, and paste – suitable for orthopaedic, spinal, and dental surgery applications.
• orthopaedic implants for animals: screws, TPLO plates, reconstruction plates, and complete surgical toolkits for trauma surgery.
The company is currently seeking distributors of veterinary products with an established market presence on local and global markets and active cooperation with veterinary clinics and hospitals, pharmacies, animal treatment centres, and veterinary professionals. Their portfolio is primarily intended for professionals. - Advantages and Innovations
-
A fast-growing biotechnology company specialising in the development and implementation of innovative solutions which is focused on creating groundbreaking healthcare products that respond to real-world needs – both human and animal.
Our competitive advantage lies in the integration of science and clinical practice.
We have our own Research & Development (R&D) department, which works closely with veterinarians and scientists, enabling us to rapidly implement innovations based on the latest scientific evidence.
Our Medical Scientific Communication department monitors the most recent publications, analyzes clinical data, and co-creates educational content to support veterinarians and partners in the effective use of our products.
In the veterinary field the company introduced several cutting-edge solutions, including:
• an advanced device for obtaining platelet-rich plasma (PRP) with a high platelet concentration.
• an innovative biomimetic bone substitute based on a synergy of hydroxyapatite and tricalcium phosphate, available in various forms (granules, blocks, paste).
• next-generation hyaluronic acid-based products for intra-articular, intravenous, and subcutaneous use, tailored to the animal's size and therapy type.
Company's innovation is also reflected in the flexibility of product implementation across new markets.
Their regulatory affairs department supports partners by preparing registration documentation tailored to local regulations, while their marketing team develops customised materials to support promotion and education.
The company operates in accordance with ISO, GMP, and HACCP standards and follow Pharmacovigilance principles, ensuring the highest level of safety and quality. It offers collaborative partnership model to its partners, based on the exchange of knowledge, delivery of training, analysis of sales data, and responding to evolving market needs. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Not relevant
Partner Sought
- Expected Role of a Partner
-
The company expects that their international partners will have experience in the distribution of specialised veterinary products, particularly those targeted at veterinarians, clinics, hospitals, and veterinary pharmacies. A thorough understanding of the local veterinary market is required, including purchasing structures, key stakeholders, and the potential of individual market segments.
The company prefers partners who:
• possess an extensive network of contacts in the veterinary sector, including clinics, practices, and wholesalers,
• have experience in launching and promoting medical or pharmaceutical products,
• operate a structured sales organisation with a team of field representatives capable of conducting promotional and educational activities for veterinarians,
• are open to an exclusive distribution model, covering the entire country,
• have experience in the registration processes of medicinal products or medical devices.
Additional advantages include:
• ownership of, or cooperation with, a certified pharmaceutical wholesaler, allowing for the legal import and distribution of veterinary medicinal products (including injectable hyaluronic acid),
• the ability to carry out marketing and educational activities, including organizing local trainings, webinars, and participating in trade shows and industry events,
• willingness to engage in a long-term partnership based on regular market feedback, sales reporting, and joint strategic planning.
To ensure the success of cooperation, the company offers comprehensive support in the following areas:
Research & Development (R&D) – enabling fast adaptation of products to local market needs,
Regulatory Affairs – supporting the partner during the registration process by preparing the required documentation,
Medical Scientific Communication – responsible for organising training sessions, developing scientific content, analysing clinical data, and preparing educational materials,
Marketing – providing modern and effective promotional materials that support local sales activities.
They prefer an exclusive distribution model (one distributor per market), which is why are particularly interested in partners with nationwide reach and the capability to successfully introduce new products into clinical practice.
Due to the presence of a veterinary medicinal product in their portfolio that can only be distributed by certified pharmaceutical wholesalers, it is preferable for the potential partner to have the necessary licenses to import and distribute veterinary medicines. However, this is not a strict requirement – depending on the market, various cooperation scenarios are possible, and they are open to discussing them. - Type and Size of Partner
- SME 11-49
- University
- R&D Institution
- SME <=10
- SME 50 - 249
- Other
- Big company
- Type of partnership
- Supplier agreement
- Commercial agreement
Dissemination
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- Targeted countries
- All countries